Cancer stromal targeting

Masahiro Yasunaga, Shino Manabe, Yasuhiro Matsumura

Research output: Contribution to journalArticlepeer-review

Abstract

Antibody-drug conjugate (ADC) targeting tumor cells themselves was effective for hematological malignancy or breast cancer having hyper- vascularity and poor stroma. However, it was not effective for the refractory tumors such as brain tumor, scirrhous gastric cancer or pancreatic cancer. Dense stroma prevents the ADC form reaching the tumor cells within the tumor tissues. To overcome "stromal barrier", we created "CAST (Cancer stromal targeting) therapy" using ADC targeting to a tumor stroma. We have succeeded in developing anti-cancer agent (SN-38) conjugated anti-collagen 4 antibody or anti-fibrin antibody. The therapy damaged both tumor cells and tumor vasculature. Bone marrow toxicity, hepatorenal disorder or autonomatous harmful immune response was not recognized. Further evaluation of the CAST therapy is necessary for a future clinical application.

Original languageEnglish
Pages (from-to)396-405
Number of pages10
JournalDrug Delivery System
Volume28
Issue number5
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • ADC
  • Antibody delivery
  • CAST therapy
  • Stroma

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Cancer stromal targeting'. Together they form a unique fingerprint.

Cite this